From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
Anti-IL5/IL5R (reslizumab, mepolizumab, benralizumab) | N = 42 | Anti-IgE (omalizumab) | N = 22 | |||
---|---|---|---|---|---|---|
Baseline | Change | P | Baseline | Change | P | |
Mean daily OCS dose (mg) a | 7.07 (0–40. SD 7.13) | −3.00 (−35–25. SD 7.91) | 0.020 | 4.82 (0–20. SD 6.50) | −2.29 (−20–0. SD 5.80) | 0.085 |
Courses of OCS b | 4.21 (0–12. SD 2.75) | −2.77 (−7.64–1. SD 2.81) | 1.47 e−07 | 2.50 (0–6. SD 1.56) | −1.32 (−4–10. SD 2.01) | 0.007 |
Courses of antibiotics b | 1.40 (0–5. SD 1.42) | −0.69 (−5–7. SD 2.08) | 0.040 | 0.95 (0–3. SD 0.93) | − 0.23 (− 3–5. SD 1.47) | 0.488 |
Emergency room visits b | 0.62 (0–8. SD 1.63) | −0.29 (−6–4. SD 1.30) | 0.159 | 0.18 (0–1. SD 0.39) | 0.18 (− 1–5. SD 1.19) | 0.492 |
Hospitalisations b | 0.52 (0–8. SD 1.42) | − 0.20 (−8–4. SD 1.63) | 0.448 | 0.45 (0–2. SD 0.66) | 0.00 (− 1–5. SD 1.21) | 1.00 |
Sick leaves b | 0.93 (0–6. SD 1.72) | − 0.58 (− 6–6. SD 1.86) | 0.053 | 0.59 (0–4. SD 1.03) | −0.14 (− 3–11. SD 1.18) | 0.602 |
Total number of exacerbation events c | 7.57 (1–26. SD 5.59) | −4.43 (− 22–13. SD 6.24) | 4.79 e− 05 | 4.68 (0–11. SD 3.40) | −1.50 (− 7–21. SD 5.55) | 0.229 |
Blood eosinophil count (E9/litre) | 0.45 (0.03–1.84. SD 0.37) | − 0.39 (− 1.79–0.01. SD 0.38) | 2.36 e− 07 | 0.43 (0–1.34. SD 0.41) | −0.08 (− 0.61–0.52. SD 0.41) | 0.433 |
Mean FEV1 (litres) | 2.27 (1.0–4.2. SD 0.78) | 0.17 (− 0.5–1.3. SD 0.41) | 0.014 | 2.83 (1.5–4.2. SD 0.86) | 0.05 (− 0.6–1.3. SD 0.54) | 0.720 |
ACT (mean) d | 15.63 (8–23. SD 4.28) | 4.46 (− 15–13. SD 5.81) | 0.0005 | 13.40 (7–22. SD 4.82) | 8.50 (2–17. SD 5.63) | 0.015 |
Exhaled nitric oxide (mean) (ppb) | 28.17 (5–110. SD 28.98) | − 4.78 (− 68–40.1. SD 18.83) | 0.759 | 35.66 (5–123. SD 36.30) | − 12.63 (− 71–21.5. SD 36.56) | 0.592 |
Serum total IgE (mean) (kU/litre) e | 290.85 (8–4672. SD 786.18) | 160 (− 304–1693. SD 551.61) | 0.424 | 313.36 (14–845. SD 248.76) | 77.83 (− 24–369. SD 133.38) | 0.249 |